Simeprevir is a protease inhibitor, which enables the deactivation of viral proteins. When taken once a day in conjuction with both ribavirin and interferon, HCV (hep C virus infection) can be treated. This combo drug will be commercially available as telaprevir with interferon and ribavarin.
Though other treatment options for Hep C exist, the unique benefit of this drug is its cost-effectiveness. Simpereveir, which is manufactured and marketed by Janssen Pharmaceuticals, provides the drug many HCV sufferers in the developing world need. Indeed, HCV often disproportionately affects the socioceonomically challenged segments of the population.
The study, which was led by Dr. Rajender Reddy, is to be published early next year in the January 2010 issue of The Lancet Infectious Diseases. The study that confirmed the potency of what Reddy and his team members thought to be an effective antiviral cocktail was a Phase 3, randomized, double-blind study on 763 adult sufferers of HCV.
An image demonstrating the multifaceted antiviral effects of simperevier from http://hepatitiscnewdrugresearch.com/uploads/2/8/0/7/2807311/8920462.png.